The federal approval comes from the Therapeutic Goods Administration under the Special Access Scheme, and your Clinician applies for it in their own name before prescribing. WA Health states that this approval is “not transferable to another prescriber”, so it stays with the practitioner who applied.
Western Australia can add a second approval, a patient-specific authorisation from the Chief Executive Officer of the Department of Health in defined situations: a patient under 18, which LeafLine does not see; a history of drug dependence, oversupply or a substance use disorder in the past five years; a history of psychosis or another psychiatric condition alongside the reason for treatment; and a daily dose above the Department’s published ceiling. Where one of these applies, your Clinician lodges the WA application with the federal one, and nothing is prescribed until both are granted.
WA Health says prescribers should check ScriptCheckWA, the state’s real-time prescription monitoring system, before prescribing, and it asks for the result in any Department application. Your Clinician tells you at the consultation whether a WA authorisation is needed in your case.
Last verified 27 October 2026. The WA Department of Health site refused connections on 27 October 2026, so the WA rules above rest on our read of its page on 1 September 2026, which listed the same four situations as our April 2026 read. The federal approval rests on the TGA page as read on 7 September 2026.
General information, not medical or legal advice. Your Clinician confirms which rules apply to you at your consultation.